Management and outcome of anthracycline cardiomyopathy

Management and outcome of anthracycline cardiomyopathy

Bibliographic Details
Main Authors:	A.A. Dhir, S.P. Sawant, A. Daddi
Format:	Article
Language:	English
Published:	Elsevier 2014-11-01
Series:	Indian Heart Journal
Online Access:	http://www.sciencedirect.com/science/article/pii/S0019483214005033

Similar Items

Outcomes in patients with anthracycline‐induced cardiomyopathy undergoing left ventricular assist devices implantation
by: Avirup Guha, et al.
Published: (2021-08-01)

Ischemic stroke as the first manifestation of anthracycline cardiomyopathy
by: G. R. Ramazanov, et al.
Published: (2023-01-01)

Pregnancy and Cardiomyopathy After Anthracyclines in Childhood
by: Kara Annette Thompson
Published: (2018-03-01)

The Role of Carvedilol in the Treatment of Dilated and Anthracyclines-Induced Cardiomyopathy
by: Makoto Kodama, et al.
Published: (2011-05-01)

State of Vegetative Homeostasis in Children with Anthracycline-Induced Cardiomyopathy
by: T.V. Shatynska, et al.
Published: (2014-03-01)

Anthracycline-induced cardiomyopathy in the long-term period after chemotherapy: clinical case
by: Nikita A. Kozjavin, et al.
Published: (2023-04-01)

Cardiomyopathy in a dog with multicentric lymphoma following treatment with several anthracyclines
by: Michihito Tagawa, et al.
Published: (2021-01-01)

A case series about the favorable effects of sacubitril/valsartan on anthracycline cardiomyopathy
by: Renato De Vecchis, et al.
Published: (2020-09-01)

Identification of novel hypermethylated or hypomethylated CpG sites and genes associated with anthracycline-induced cardiomyopathy
by: Purnima Singh, et al.
Published: (2023-08-01)

Anthracyclines
by: Alison Cheong, et al.
Published: (2018-12-01)

Early myocardial oedema can predict subsequent cardiomyopathy in high‐dose anthracycline therapy
by: Fabian Muehlberg, et al.
Published: (2023-02-01)

Evaluating anthracycline cardiotoxicity associated single nucleotide polymorphisms in a paediatric cohort with early onset cardiomyopathy
by: Timothy N. McOwan, et al.
Published: (2020-05-01)

Creation of anthracycline prodrug
by: A. N. Tevyashova
Published: (2014-12-01)

The Lack of Synergy between Carvedilol and the Preventive Effect of Dexrazoxane in the Model of Chronic Anthracycline-Induced Cardiomyopathy
by: Jaroslaw Szponar, et al.
Published: (2023-06-01)

Approaches for monitoring and treating cardiomyopathy among cancer survivors following anthracycline or thoracic radiation treatment
by: Arash Delavar, et al.
Published: (2022-05-01)

Late-onset cardiomyopathy among survivors of childhood lymphoma treated with anthracyclines: a systematic review
by: Despoina-Rafailia Benetou, et al.
Published: (2019-05-01)

CardioMEMS-Guided CAR T Cell Therapy for Lymphoma in a Patient With Anthracycline-Induced Cardiomyopathy
by: Anthony J. Kanelidis, MD, et al.
Published: (2020-09-01)

Correction: Approaches for monitoring and treating cardiomyopathy among cancer survivors following anthracycline or thoracic radiation treatment
by: Arash Delavar, et al.
Published: (2022-08-01)

Pregnancy outcomes related to the treatment of sarcomas with anthracyclines and/or ifosfamide during pregnancy
by: Devon Miller, et al.
Published: (2022-09-01)

Genetics of Anthracycline-Associated Cardiotoxicity
by: Talal Khalid Al-Otaibi, et al.
Published: (2022-04-01)

Cardiac miRNA expression during the development of chronic anthracycline-induced cardiomyopathy using an experimental rabbit model
by: Michaela Adamcova, et al.
Published: (2024-01-01)

Disclosing an In-Frame Deletion of the Titin Gene as the Possible Predisposing Factor of Anthracycline-Induced Cardiomyopathy: A Case Report
by: Yu-Wei Chang, et al.
Published: (2022-08-01)

Dexrazoxane in anthracycline cardiotoxicity
by: Abhijit S Nair
Published: (2017-01-01)

Anthracycline-Induced Cardiotoxicity
by: Radomír Hrdina, et al.
Published: (2000-01-01)

Anthracycline-Induced Cardiotoxicity
by: Jennifer E. Liu, MD
Published: (2020-03-01)

Prevention and management of anthracycline induced cardiotoxicity: A review
by: Ian Osoro, et al.
Published: (2022-12-01)

Anthracyclines: a cornerstone in the management of non-Hodgkin’s lymphoma
by: Stefano Luminari, et al.
Published: (2011-10-01)

Effect of anthracyclines and isoflurane on QTc interval
by: A. Venugopal, et al.
Published: (2014-01-01)

Disruption of a GATA4/Ankrd1 signaling axis in cardiomyocytes leads to sarcomere disarray: implications for anthracycline cardiomyopathy.
by: Billy Chen, et al.
Published: (2012-01-01)

Assessing cardiotoxicity in randomised trials of anthracycline chemotherapy
by: Kerr, A
Published: (2016)

Genetic basis of anthracyclines cardiotoxicity: Literature review
by: M. Yu. Sinitsky, et al.
Published: (2021-10-01)

Anthracycline-induced cardiotoxicity and senescence
by: Laura K. Booth, et al.
Published: (2022-11-01)

Anthracycline-Induced Vascular Dysfunction
by: Douglas B. Sawyer, MD, PhD
Published: (2020-09-01)

The role of iron in anthracycline cardiotoxicity
by: Elena eGammella, et al.
Published: (2014-02-01)

The cardiovascular system in patients with anthracycline cardiomiopathy
by: Alexandr T. Teplyakov, et al.
Published: (2017-10-01)

Altered Peripheral Blood Gene Expression in Childhood Cancer Survivors With Anthracycline‐Induced Cardiomyopathy – A COG‐ALTE03N1 Report
by: Purnima Singh, et al.
Published: (2023-10-01)

The Effect of Anthracycline Chemotherapy on Arterial Stiffness
by: Mürsel Şahin, et al.
Published: (2020-06-01)

Novel Therapeutics for Anthracycline Induced Cardiotoxicity
by: Jacqueline T. Vuong, et al.
Published: (2022-04-01)

Risk Factors for Anthracycline-Induced Cardiotoxicity
by: Shuo Qiu, et al.
Published: (2021-09-01)

Candidate Plasma Biomarkers to Detect Anthracycline‐Related Cardiomyopathy in Childhood Cancer Survivors: A Case Control Study in the Dutch Childhood Cancer Survivor Study
by: Jan M. Leerink, et al.
Published: (2022-07-01)